
    
      After obtaining informed consent, subjects who meet the inclusion criteria and not violating
      the exclusion criteria will be enrolled to receive Harnalidge速 OCAS速 0.4 mg for treatment.
      The interventional period for the study is three months after the first date of enrollment or
      until the patients are discontinued the treatment of Harnalidge速 OCAS速. All subjects will be
      instructed to contact the site if a patient's partner becomes pregnant during or within 90
      days from the discontinuation of dosing, the investigator should report the information to
      the sponsor as if it is an SAE.
    
  